Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2021-06-29 Regulatory Filings
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-06-29 English
FORM 8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement for the acquisition of Corlieve Therapeutics, including financial terms and development plans. It also references press releases about the acquisition and clinical data updates. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is primarily an announcement of a significant transaction and related events, fitting the category of M&A Activity (TAR). The length (6381 characters) and detailed description of the transaction support this classification rather than a brief announcement or a regulatory filing fallback. Therefore, the filing type is M&A Activity (TAR) with high confidence.
2021-06-23 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 15, 2021, by uniQure N.V. It reports the appointment of a new Chief Financial Officer and details the results of the Annual General Meeting (AGM) held on June 16, 2021. The document includes voting results on various agenda items such as adoption of annual accounts, discharge of the board, reappointments of directors, amendments to share plans, and other shareholder resolutions. The content focuses on management changes and shareholder voting outcomes rather than full financial statements or detailed financial performance. Therefore, the document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA). The length of the document (9670 characters) and detailed voting results support this classification rather than a brief announcement or a full annual report.
2021-06-21 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-21 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-17 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.